The European Medicines Agency said last week that it was initiating a review of the combined use of agents that block the renin-angiotensin system (RAS). The three classes of RAS-blocking drugs (ACE i… more →
CardioBriefwrote 1 day ago: The European Medicines Agency said last week that it was initiating a review of the combined use of … more →
wrote 4 days ago: In the crucial early stages of a possible heart attack, EMTs on the scene now rely on slow and unrel … more →
wrote 5 days ago: An Institute of Medicine report on salt earlier this week sparked a lot of controversy. The report c … more →
wrote 1 week ago: Significant questions about research misconduct have been raised about a prominent Japanese cardiova … more →
wrote 2 weeks ago: Burton Sobel, a towering scientist and cardiologist, died at home on May 3 at the age of 75. Sobel h … more →
wrote 2 weeks ago: The FDA has approved a new combination drug from Merck for lowering cholesterol. The drug, which wil … more →
wrote 2 weeks ago: A meta-analysis published in the journal Heart has been retracted. As Adam Marcus writes in Retracti … more →
wrote 2 weeks ago: A Japanese research scandal, which has so far centered on actions taken by the once-prominent cardio … more →
wrote 2 weeks ago: A large observational study found no increased risk for cardiovascular events associated with azithr … more →
wrote 2 weeks ago: The FDA has issued a drug safety communication concerning tolvaptan (Samsca, Otsuka), a selective va … more →
wrote 3 weeks ago: Here are two small but important changes in the anticoagulation field: FDA approves new product for … more →
wrote 3 weeks ago: (Updated) Earlier this week the stock of Edwards Lifesciences tanked after the company announced wea … more →
wrote 3 weeks ago: A new study from the Cleveland Clinic research group headed by Stanley Hazen offers more evidence in … more →
wrote 4 weeks ago: Shalom “Shal” Jacobovitz will be the new chief executive officer of the American College … more →
wrote 4 weeks ago: In recent years the FDA has come under increasing fire for approving drugs on the basis of surrogate … more →
wrote 1 month ago: Although the internet represents “a new frontier in medicine” for physicians and patient … more →
wrote 1 month ago: In response to my post yesterday about why health stories should nearly always be received with caut … more →
wrote 1 month ago: Once again the controversial diabetes drug rosiglitazone (Avandia, GlaxoSmithKline) will be the subj … more →
wrote 1 month ago: Don’t believe the the hype! That’s the cardinal rule to obey when reading health news. … more →